[go: up one dir, main page]

PA8546001A1 - A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT IN COMBINATION TO TREAT OBSTRUCTIVE DISEASES OF RESPIRATORY ROADS - Google Patents

A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT IN COMBINATION TO TREAT OBSTRUCTIVE DISEASES OF RESPIRATORY ROADS

Info

Publication number
PA8546001A1
PA8546001A1 PA20028546001A PA8546001A PA8546001A1 PA 8546001 A1 PA8546001 A1 PA 8546001A1 PA 20028546001 A PA20028546001 A PA 20028546001A PA 8546001 A PA8546001 A PA 8546001A PA 8546001 A1 PA8546001 A1 PA 8546001A1
Authority
PA
Panama
Prior art keywords
polinergic
agent
combination
pde4 inhibitor
obstructive diseases
Prior art date
Application number
PA20028546001A
Other languages
Spanish (es)
Inventor
Michael Yeadon
John W Watson
Roisin A Armstrong
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129396A external-priority patent/GB0129396D0/en
Priority claimed from GB0210240A external-priority patent/GB0210240D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PA8546001A1 publication Critical patent/PA8546001A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION SE RELACIONA CON UNA COMBINACION DE UN INHIBIDOR SELECTIVO DE PDE4 Y UN AGENTE ANTICOLINERGICO PARA LA ADMINISTRACION SIMULTANEA, SECUENCIAL O POR SEPARADO POR LA VIA INHALADA EN EL TRATAMIENTO DE UNA ENFERMEDAD OBSTRUCTIVA DE LAS VIAS RESPIRATORIAS U OTRAS ENFERMEDADES INFLAMATORIAS, CON LA CONDICION DE QUE EL AGENTE ANTICOLINERGICO NO SEA UNA SAL DE TIOTROPIO.THIS INVENTION IS RELATED TO A COMBINATION OF A SELECTIVE PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT FOR SIMULTANEOUS, SEQUENTIAL OR SEPARATE ADMINISTRATION BY THE INHALED ROAD IN THE TREATMENT OF AN OBSTRUCTIVE DISEASE OF THE RESPIRATORY VIEWS OR OTHER INFORMATION THAT THE ANTI-POLINERGIC AGENT IS NOT A TIOTROPIO SALT.

PA20028546001A 2001-05-25 2002-05-24 A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT IN COMBINATION TO TREAT OBSTRUCTIVE DISEASES OF RESPIRATORY ROADS PA8546001A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29360601P 2001-05-25 2001-05-25
GB0129396A GB0129396D0 (en) 2001-12-07 2001-12-07 Pharmaceutical combination
GB0210240A GB0210240D0 (en) 2002-05-03 2002-05-03 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
PA8546001A1 true PA8546001A1 (en) 2003-12-30

Family

ID=27256347

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028546001A PA8546001A1 (en) 2001-05-25 2002-05-24 A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT IN COMBINATION TO TREAT OBSTRUCTIVE DISEASES OF RESPIRATORY ROADS

Country Status (25)

Country Link
US (1) US20040147544A1 (en)
EP (1) EP1395288A1 (en)
JP (1) JP2005508861A (en)
KR (1) KR20040007605A (en)
CN (1) CN1511042A (en)
AP (1) AP2003002909A0 (en)
BG (1) BG108382A (en)
BR (1) BR0209992A (en)
CA (1) CA2446613A1 (en)
CO (1) CO5640041A2 (en)
CR (1) CR7152A (en)
CZ (1) CZ20033150A3 (en)
EE (1) EE200300585A (en)
HU (1) HUP0400037A2 (en)
IL (1) IL158776A0 (en)
MA (1) MA27027A1 (en)
MX (1) MXPA03010162A (en)
NO (1) NO20035204D0 (en)
NZ (1) NZ529335A (en)
OA (1) OA12610A (en)
PA (1) PA8546001A1 (en)
PL (1) PL367085A1 (en)
SK (1) SK14312003A3 (en)
TN (1) TNSN03123A1 (en)
WO (1) WO2002096463A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
DE10230769A1 (en) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drug compositions based on new anticholinergics and PDE-IV inhibitors
EP1610787B1 (en) * 2003-03-28 2008-01-23 Nycomed GmbH Synergistic combination comprising roflumilast and an anticholinergic agent selected from tiotropium salts for the treatment of respiratory diseases
MXPA05010161A (en) * 2003-03-28 2005-11-16 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases.
CN101518532A (en) * 2004-02-06 2009-09-02 Meda制药有限及两合公司 Combination of anticholinergics and phosphodiesterase type 4 inhibitors for the treatment of respiratory diseases
JP2007520509A (en) * 2004-02-06 2007-07-26 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト Rhinitis treatment with anticholinergic drugs or in combination with antihistamines, phosphodiesterase 4 or corticosteroids
PT1713473E (en) 2004-02-06 2013-05-13 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
WO2005102344A1 (en) * 2004-04-27 2005-11-03 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical composition
DE602004015788D1 (en) * 2004-08-19 2008-09-25 Rottapharm Spa Use of phenylbenzamide derivatives for the treatment of chronic obstructive pulmonary disease (COPD)
CN101128196B (en) 2005-03-16 2013-01-02 Meda制药有限及两合公司 Combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
KR100696432B1 (en) * 2005-08-31 2007-03-19 김용환 Medical Panties
RU2008119322A (en) * 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) COMPOSITIONS OF PHOSPHODIESTHESIS INHIBITORS TYPE IV
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
NZ568349A (en) 2005-12-21 2011-05-27 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552407A (en) * 1993-06-11 1996-09-03 New York University Medical Center Anhydroecgonine compounds and their use as anticholinergic agents
SK282167B6 (en) * 1995-06-06 2001-11-06 Pfizer Inc. Tricyclic 5,6-dihydro-9h-pyrazol[3,4-c]-1,2,4-triazolo[4,3-a] pyridines and pharmaceutical preparation based on them
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors

Also Published As

Publication number Publication date
BG108382A (en) 2004-12-30
IL158776A0 (en) 2004-05-12
TNSN03123A1 (en) 2005-12-23
EE200300585A (en) 2004-04-15
HUP0400037A2 (en) 2004-04-28
JP2005508861A (en) 2005-04-07
OA12610A (en) 2006-06-09
US20040147544A1 (en) 2004-07-29
AP2003002909A0 (en) 2003-12-31
MXPA03010162A (en) 2004-03-10
CR7152A (en) 2004-02-23
CZ20033150A3 (en) 2004-06-16
KR20040007605A (en) 2004-01-24
NO20035204D0 (en) 2003-11-24
CN1511042A (en) 2004-07-07
BR0209992A (en) 2004-04-06
EP1395288A1 (en) 2004-03-10
MA27027A1 (en) 2004-12-20
SK14312003A3 (en) 2004-08-03
WO2002096463A1 (en) 2002-12-05
CA2446613A1 (en) 2002-12-05
CO5640041A2 (en) 2006-05-31
PL367085A1 (en) 2005-02-21
NZ529335A (en) 2005-09-30

Similar Documents

Publication Publication Date Title
PA8546001A1 (en) A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT IN COMBINATION TO TREAT OBSTRUCTIVE DISEASES OF RESPIRATORY ROADS
PA8546101A1 (en) AN A2A ANTAGONIST IN COMBINATION WITH AN ANTI-POLINERGIC AGENT FOR THE TREATMENT OF OBSTRUCTIVE DISEASES OF THE AIRWAYS
BR0205722A (en) Prolonged release formulation and method for treating a patient suffering from pain
CL2004001170A1 (en) INHALABLE PHARMACEUTICAL COMBINATION CONTAINING (A) FORMOTEROL, OR A SALT, OR A SOLVATE OF IT OR THE SALT AND (B) MOMETASONE FUROATE; PHARMACEUTICAL CASE THAT UNDERSTANDS IT; AND ITS USE IN THE THERAPY OF AN INFLAMMATORY OR OBSTRUCTIVE DISEASE OF THE V
BRPI0410503A (en) use of ivermectin for the manufacture of a topical pharmaceutical composition, topical composition and use of the composition
BR0307050A (en) Compound, pharmaceutical composition, methods for treating prostaglandin d2 mediated diseases, for treating nasal congestion, for treating allergic asthma, and for treating allergic rhinitis, pharmaceutically acceptable salt, and use of a compound or salt
PA8529701A1 (en) RETINOID COMPOUNDS
AR054139A1 (en) MODIFIED FORMATION AND IMMEDIATE RELEASE OF MEMANTINE SPHERES
BR0207883A (en) Anticholenergic and pde-iv inhibitor drug compositions
BRPI0407662B8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
CR8850A (en) COMPOSITION AND METHOD TO TREAT HEMORROIDS AND / OR ANO-RECTURAL DISORDERS
DE50109156D1 (en) MEDICINE TO TREAT DISORDERS OF THE TRACHEO BRONCHIAL TRAIN, IN PARTICULAR THE COPD
CY1116938T1 (en) HUNTINGTON AND OTHER POLYGLUTAMINE DISEASE REFUNDS
BRPI0409796A (en) use of dipyridamole or mopidamole for treatment and prevention of thromboembolic disorders and disorders caused by excessive thrombin formation and / or elevated expression of thrombin receptors
UY27505A1 (en) CHEATABLE TABLET CONTAINING LISINA
ATE357912T1 (en) INTRACORPORAL MEDICATIONS FOR HIGH-ENERGY PHOTOTHERAPEUTIC TREATMENT OF DISEASES
SV2003001056A (en) A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT IN COMBINATION TO TREAT OBSTRUCTIVE DISEASES OF RESPIRATORY ROADS
DE60019947D1 (en) PREVENTION OF COLORECTAL CANCER
BRPI0508053A (en) method of combating toxicity caused by an antifolate compound, and of treating a disease, uses enzyme having carboxy-peptidase g activity, antifolate compound, folate route rescue agent, and enzyme having carboxide activity. peptidase g and a folate route rescue agent, therapeutic system, and ex vivo method of cleaving a terminal 1-glutamate group of a compound, determining the rate and / or extent of cleavage of a compound, and cleavage of a compound
HN2001000204A (en) AMIDAS OF SUBSTITUTED PHENILCICLOHEXANOCARBOXILICO ACID AND ITS USE
PA8560601A1 (en) PHARMACEUTICAL COMBINATION
HN2001000214A (en) PHENOXYPHENYL ALCANOSULPHONATES
BR0317780A (en) Suppository formulation for rectal administration, method for treating hemorrhoids, and use of thrombolytically acting peptides and proteins for treating hemorrhoids
UY27307A1 (en) A PDE4 INHIBITOR AND AN ANTI-POLYNERGIC AGENT IN COMBINATION TO TREAT OBSTRUCTIVE DISEASES OF RESPIRATORY ROUTES
AR030660A1 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AN ILLNESS ASSOCIATED WITH AN EXCESS OF IL-12 PRODUCTION